Company: SCLXW
Filing Date: 2025-01-22
Form Type: 8-K
Source: 0001193125-25-009911
Chunk: 1

Company: Scilex Holding Co
Filing Date: 2025-01-22
Form: 8-K
Item: Item 1.01
Chunk 1
---
 Oramed or (B) the outstanding principal amount of all of the Tranche B Notes in accordance with each Last Out Holder’s Last Out Pro Rata Share (as defined in the Agreement Among Holders) at such time. In addition, the parties agreed to add an additional covenant to the Oramed Note, preventing any increase in compensation or additional incentive equity awards to any officer, director or member of senior management of the Company or the Company’s subsidiaries while the Oramed Note remains outstanding.

The representations and warranties contained in the Oramed Amendment were made only for purposes of such Oramed Amendment and as of specific dates, were solely for the benefit of the parties to the Oramed Amendment, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Oramed Amendment is incorporated herein by reference only to provide investors with information regarding the terms of the Oramed Amendment, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Securities and Exchange Commission.

The foregoing summary of the Oramed Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Oramed Amendment, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.